Wednesday, Heron Therapeutics Inc. (HRTX) announced that the FDA has approved the Prior Approval Supplement Application for the Zynrelef Vial Access Needle or VAN. Following this announcement, the stock is up 4% in pre-market trading.
The VAN is designed to streamline aseptic preparation while cutting withdrawal time to between 20 and 45 seconds. This new design replaces the existing vented vial spike with a more user-friendly, container-like option, which could lead to safer usage, greater adoption, and improved preparation efficiency.
The company anticipates the VAN's release in the fourth quarter of 2024.
In pre-market activity on the Nasdaq, the shares are trading at $2.04, up 4.12%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.